Subtopic Deep Dive
Tyrosine Kinase Inhibitor Resistance Mechanisms
Research Guide
What is Tyrosine Kinase Inhibitor Resistance Mechanisms?
Tyrosine kinase inhibitor resistance mechanisms in chronic myeloid leukemia refer to molecular pathways, including BCR-ABL1 kinase domain mutations, amplification, and efflux pump overexpression, that cause acquired resistance to TKIs like imatinib in CML patients.
These mechanisms drive progression from chronic phase to blast crisis despite TKI therapy. Key processes involve BCR-ABL1 oncoprotein activity leading to genetic instability and impaired DNA repair (Perrotti et al., 2010; 388 citations). Over 20 years of kinase inhibitor research highlight ongoing challenges in overcoming resistance (Cohen et al., 2021; 980 citations).
Why It Matters
Understanding TKI resistance enables combination therapies targeting BCR-ABL1 persistence and leukemia stem cells, improving long-term CML survival rates beyond 90% with first-line imatinib (Quintás-Cardama and Cortes, 2008). Resistance linked to blast crisis from continued BCR-ABL activity causes DNA damage, informing strategies like venetoclax addition for BCL-2 inhibition (Hehlmann, 2012; Cang et al., 2015). Clinical management guidelines emphasize monitoring kinase domain mutations to switch TKIs early, reducing blast transformation risk (Steegmann et al., 2016).
Key Research Challenges
BCR-ABL1 Kinase Domain Mutations
Point mutations in the BCR-ABL1 kinase domain prevent TKI binding, leading to treatment failure in chronic phase CML (Quintás-Cardama and Cortes, 2008). These mutations arise from BCR-ABL1-induced genomic instability (Perrotti et al., 2010). Sequential TKI switching addresses some but not all variants (Cohen et al., 2021).
Leukemia Stem Cell Persistence
CML stem cells resist TKIs due to BCR-ABL1-independent quiescence and survival pathways (Holyoake and Vetrie, 2017). These LSCs drive relapse post-TKI cessation despite deep molecular responses. Targeting BCL-2 shows promise in preclinical models (Cang et al., 2015).
BCR-ABL1-Independent Pathways
Activation of Src kinases and efflux pumps like ABCG2 overexpress to expel TKIs, bypassing BCR-ABL1 inhibition (Iqbal and Iqbal, 2014). Epigenetic changes and blastic transformation amplify resistance (Hehlmann, 2012). Multi-kinase inhibitors like dasatinib add toxicity risks without fully resolving (Guignabert et al., 2016).
Essential Papers
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen, Darren A.E. Cross, Pasi A. Jänne · 2021 · Nature Reviews Drug Discovery · 980 citations
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Alfonso Quintás‐Cardama, Jörge E. Cortes · 2008 · Blood · 739 citations
Abstract Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on t...
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Juan Luis Steegmann, Michele Baccarani, Massimo Breccia et al. · 2016 · Leukemia · 462 citations
Imatinib: A Breakthrough of Targeted Therapy in Cancer
Nida Iqbal, Naveed Iqbal, Naveed Iqbal et al. · 2014 · Chemotherapy Research and Practice · 455 citations
Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approac...
Chronic myeloid leukemia: mechanisms of blastic transformation
Danilo Perrotti, Catriona Jamieson, John M. Goldman et al. · 2010 · Journal of Clinical Investigation · 388 citations
The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease usually respond to treatment ...
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
Sunitha Shyam Sunder, Umesh C. Sharma, Saraswati Pokharel · 2023 · Signal Transduction and Targeted Therapy · 356 citations
Abstract Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant ut...
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake, David Vetrie · 2017 · Blood · 301 citations
Abstract Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self-renews, pr...
Reading Guide
Foundational Papers
Start with Quintás-Cardama and Cortes (2008; 739 citations) for BCR-ABL1 molecular basis, then Perrotti et al. (2010; 388 citations) for transformation mechanisms, and Iqbal and Iqbal (2014; 455 citations) for TKI origins.
Recent Advances
Study Cohen et al. (2021; 980 citations) for 20-year TKI progress, Holyoake and Vetrie (2017; 301 citations) for stem cell persistence, and Shyam Sunder et al. (2023; 356 citations) for adverse effects.
Core Methods
Kinase domain sequencing for mutations; CRISPR models for pathway validation; patient-derived xenografts for LSC testing; efflux assays for pump activity (Cohen et al., 2021; Perrotti et al., 2010).
How PapersFlow Helps You Research Tyrosine Kinase Inhibitor Resistance Mechanisms
Discover & Search
Research Agent uses citationGraph on Quintás-Cardama and Cortes (2008; 739 citations) to map 50+ connected papers on BCR-ABL1 resistance, then exaSearch for 'CML TKI efflux pumps' to uncover BCR-ABL-independent mechanisms cited in Cohen et al. (2021). findSimilarPapers expands to 201 recent works on stem cell persistence.
Analyze & Verify
Analysis Agent applies readPaperContent to Perrotti et al. (2010) for mutation spectra extraction, then runPythonAnalysis with pandas to quantify kinase domain mutation frequencies across 10 papers. verifyResponse via CoVe cross-checks claims against Holyoake and Vetrie (2017), with GRADE scoring evidence on LSC resistance strength.
Synthesize & Write
Synthesis Agent detects gaps in TKI combination therapies via contradiction flagging between Steegmann et al. (2016) guidelines and Cang et al. (2015) BCL-2 data, generating exportMermaid diagrams of resistance cascades. Writing Agent uses latexEditText and latexSyncCitations to draft review sections citing 20 papers, with latexCompile for figure-integrated PDF.
Use Cases
"Analyze mutation frequencies in TKI resistance from 2008-2023 CML papers"
Research Agent → searchPapers('CML TKI kinase mutations') → Analysis Agent → runPythonAnalysis(pandas aggregation of mutation counts from Perrotti et al. 2010 + 15 similars) → matplotlib survival curves output.
"Write LaTeX review on CML stem cell TKI resistance mechanisms"
Synthesis Agent → gap detection (Holyoake 2017 vs Cohen 2021) → Writing Agent → latexEditText(draft pathways) → latexSyncCitations(20 papers) → latexCompile(PDF with resistance signaling figure).
"Find code for BCR-ABL1 mutation modeling in CML resistance"
Research Agent → paperExtractUrls(Quintás-Cardama 2008) → Code Discovery → paperFindGithubRepo → githubRepoInspect(pull simulation scripts) → runPythonAnalysis(execute mutation fitness models).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TKI resistance papers: searchPapers → citationGraph → DeepScan (7-step verifyResponse/CoVe on mutation claims). Theorizer generates hypotheses on efflux pump + LSC synergies from Perrotti (2010) and Holyoake (2017). DeepScan analyzes blast crisis risks with GRADE grading of Hehlmann (2012) evidence.
Frequently Asked Questions
What defines TKI resistance mechanisms in CML?
TKI resistance arises from BCR-ABL1 kinase mutations, gene amplification, and stem cell quiescence, leading to TKI failure (Quintás-Cardama and Cortes, 2008; Perrotti et al., 2010).
What are main methods to study these mechanisms?
Sequencing identifies kinase mutations; flow cytometry detects LSC persistence; preclinical models test efflux inhibitors (Holyoake and Vetrie, 2017; Cohen et al., 2021).
What are key papers on TKI resistance?
Quintás-Cardama and Cortes (2008; 739 citations) details BCR-ABL1 biology; Perrotti et al. (2010; 388 citations) covers blastic transformation; Cohen et al. (2021; 980 citations) reviews progress.
What open problems remain?
Eradicating TKI-persistent LSCs and overcoming BCR-ABL-independent pathways lack approved therapies; combination strategies need clinical validation (Holyoake and Vetrie, 2017; Steegmann et al., 2016).
Research Chronic Myeloid Leukemia Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Tyrosine Kinase Inhibitor Resistance Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers